Talaris Therapeutics

Talaris Therapeutics, Inc. engages in cell therapy. It develops methods of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Its technologies are used to treat inherited metabolic enzyme disorders, red blood cell disorders to induce tolerance to organ transplants, and to treat autoimmune disorders such as type 1 diabetes, multiple sclerosis, rheumatoid arthritis, and scleroderma. The company was founded by Suzanne Ildstad on February 15, 2002 and is headquartered in Louisville, KY.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tourmaline Bio, Inc. is a late-stage clinical biotechnology company, which engages in the development of medicines for patients with life-altering immune diseases. It offers the TOUR006. The company was founded by Sandeep Kulkarni on September 17, 2021 and is headquartered in New York, NY.

BOSTON and LOUISVILLE, Ky., May 31, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 10:30 AM ET at the Marriott Marquis in New York, NY.

Talaris Therapeutics to Present at the Jefferies Healthcare Conference

BOSTON and LOUISVILLE, Ky., May 17, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced today announced that Scott Requadt, Chief Executive Officer of Talaris, will be presenting virtually at the H.C. Wainwright Global Investment Conference being held May 23-25, 2022.

Talaris Therapeutics to Present at the H.C. Wainwright Global Investment Conference

BOSTON and LOUISVILLE, Ky., May 17, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced the appointment of independent director Karen Smith, M.D., Ph.D., MBA, LLM to the Company's Board of Directors.

Talaris Therapeutics Announces Changes to Board of Directors

Multiple presentations pending at upcoming American Transplant Congress (ATC), as well as concurrent update on ongoing Phase 3 (FREEDOM-1) clinical trial in living donor kidney transplant (LDKT) patients

Talaris Therapeutics Announces First Quarter Financial Results and Corporate Update

BOSTON and LOUISVILLE, Ky., May 02, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced upcoming data presentations at the American Transplant Congress (ATC) taking place June 4-8, 2022.

Talaris Therapeutics Announces Upcoming Presentations at American Transplant Congress

Low rate of COVID-19 infection observed in vaccinated, durably  chimeric patients off immunosuppression

Talaris Therapeutics Presents Data on COVID-19 Outcomes Among Kidney Transplant Patients Treated with FCR001

BOSTON and LOUISVILLE, Ky., March 22, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune disorders, today announced that members of its senior management team will participate at the following investor conferences:

Talaris Therapeutics to Participate at Two Upcoming Investor Conferences

Phase 3 (FREEDOM-1) clinical trial in living donor kidney transplant (LDKT) patients continues; additional data update expected mid-year 2022

Talaris Therapeutics Announces Fourth Quarter and Year-End Financial Results

BOSTON and LOUISVILLE, Ky., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 8:40 AM ET.

Talaris Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

BOSTON and LOUISVILLE, Ky., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 2:15 PM ET.

Talaris Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

BOSTON and LOUISVILLE, Ky., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10-13, 2022.

Talaris Therapeutics to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

BOSTON and LOUISVILLE, Ky., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc., (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced that the company has been added to the NASDAQ Biotechnology Index (NASDAQ: NBI), active prior to market open today.

Talaris Therapeutics Announces Addition to the Nasdaq Biotechnology Index

Analysis confirms FCR001 induced durable tolerance in highly mismatched related and unrelated recipients Analysis confirms FCR001 induced durable tolerance in highly mismatched related and unrelated recipients

Talaris Therapeutics Presents High-Resolution Analysis of HLA Mismatching in Phase 2 Trial in Living Donor Kidney Transplant

FREEDOM-3 trial will evaluate the safety and efficacy of the company's investigational allogeneic cell therapy, FCR001, to treat severe cases of diffuse cutaneous systemic sclerosis (dcSSc) FREEDOM-3 trial will evaluate the safety and efficacy of the company's investigational allogeneic cell therapy, FCR001, to treat severe cases of diffuse cutaneous systemic sclerosis (dcSSc)

Talaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Individuals with a Severe Form of Scleroderma

Provided initial clinical update from its Phase 3 (FREEDOM-1) clinical trial evaluating FCR001 in living donor kidney transplant patients

Talaris Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update

BOSTON and LOUISVILLE, Ky., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced that members of its senior management team will participate at the following investor conferences:

Talaris Therapeutics to Participate at Three Upcoming Virtual Investor Conferences

BOSTON and LOUISVILLE, Ky., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company, today provided the first clinical update on its Phase 3 FREEDOM-1 study in living donor kidney transplant (LDKT) recipients, and also separately presented a clinical update and additional data from ongoing follow-up of its fully-enrolled Phase 2 study in LDKT recipients at the 2021 American Society of Nephrology (ASN) meeting.

Talaris Therapeutics Provides First FREEDOM-1 Phase 3 Clinical Update and Presents Additional Phase 2 Data and Analyses at American Society of Nephrology Meeting

FREEDOM-2 trial will evaluate the potential for the company's investigational allogeneic cell therapy, FCR001, to induce durable immune tolerance in patients who have previously received a kidney from a living donor FREEDOM-2 trial will evaluate the potential for the company's investigational allogeneic cell therapy, FCR001, to induce durable immune tolerance in patients who have previously received a kidney from a living donor

Talaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Delayed Tolerance Induction

BOSTON and LOUISVILLE, Ky., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company, today announced upcoming data presentations at the American Society of Nephrology (ASN) Kidney Week 2021, taking place November 4-7, 2021.

Talaris Therapeutics Announces Upcoming Presentations and Investor Conference Call During American Society of Nephrology Meeting

BOSTON and LOUISVILLE, Ky., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced that members of its senior management team will participate at the following investor conferences:

Talaris Therapeutics to Participate at Two Upcoming Virtual Investor Conferences

BOSTON and LOUISVILLE, Ky., June 14, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today reported financial results for the three-month period ended March 31, 2021, and provided an update on its business.

Talaris Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update

BOSTON and LOUISVILLE, Ky. , May 11, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced the closing of its initial public offering of 8,825,000 shares of its common stock at a price to the public of $17.00 per share. The gross proceeds of the offering were approximately $150.0 million, before deducting underwriting discounts and commissions and other offering expenses. The shares began trading on the Nasdaq Global Market on May 7, 2021 under the symbol “TALS.” All shares in the offering were offered by Talaris Therapeutics. In addition, the underwriters have a 30-day option to purchase up to an additional 1,323,750 shares of common stock at the initial public offering price less underwriting discounts and commissions.

Talaris Therapeutics Announces Closing of Initial Public Offering

Five Star Bancorp

Anebulo Pharmaceuticals

Bowman Consulting Group

Honest Co

Maquia Capital Acquisition Corp

Onion Global Ltd

Gyroscope Therapeutics Holdings

Waterdrop

Eight IPOs and four SPACs went public this past week. The week's best performer, Sacramento bank Five Star Bancorp (FSBC) priced at the high end to raise $105 million at a $325 million market cap.

U.S. IPO Weekly Recap: Sacramento Bank Five Star Bancorp Finishes On Top In An 8 IPO Week

Waterdrop, Talaris Therapeutics, Anebulo Pharmaceuticals and Bowman Consulting Group are making their public equities market debuts on Friday.

4 Companies Open for Trading

BOSTON and LOUISVILLE, Ky., May 06, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc., a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced the pricing of its initial public offering of 8,825,000 shares of common stock at a price to the public of $17.00 per share. All shares are being offered by Talaris. The gross proceeds to Talaris from the offering, before deducting underwriting discounts, commissions and other offering expenses, are expected to be approximately $150.0 million. The shares are expected to begin trading on The Nasdaq Global Select Market under the ticker symbol “TALS” on May 7, 2021. The offering is expected to close on May 11, 2021, subject to the satisfaction of customary closing conditions. In addition, the underwriters have a 30-day option to purchase up to an additional 1,323,750 shares of common stock at the initial public offering price less underwriting discounts and commissions.

News for Talaris Therapeutics Stock (TALS)